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Effect of HSV-2 infection on subsequent HIV acquisition: 
an updated systematic review and meta-analysis
Katharine J Looker*, Jocelyn A R Elmes*, Sami L Gottlieb, Joshua T Schiffer, Peter Vickerman, Katherine M E Turner, Marie-Claude Boily
Summary
Background HIV and herpes simplex virus type 2 (HSV-2) infections cause a substantial global disease burden and are 
epidemiologically correlated. Two previous systematic reviews of the association between HSV-2 and HIV found 
evidence that HSV-2 infection increases the risk of HIV acquisition, but these reviews are now more than a decade old.
Methods For this systematic review and meta-analysis, we searched PubMed, MEDLINE, and Embase (from Jan 1, 2003, 
to May 25, 2017) to identify studies investigating the risk of HIV acquisition after exposure to HSV-2 infection, either 
at baseline (prevalent HSV-2 infection) or during follow-up (incident HSV-2 infection). Studies were included if they 
were a cohort study, controlled trial, or case-control study (including case-control studies nested within a cohort study 
or clinical trial); if they assessed the effect of pre-existing HSV-2 infection on HIV acquisition; and if they determined 
the HSV-2 infection status of study participants with a type-specific assay. We calculated pooled random-effect 
estimates of the association between prevalent or incident HSV-2 infection and HIV seroconversion. We also extended 
previous investigations through detailed meta-regression and subgroup analyses. In particular, we investigated the 
effect of sex and risk group (general population vs higher-risk populations) on the relative risk (RR) of HIV acquisition 
after prevalent or incident HSV-2 infection. Higher-risk populations included female sex workers and their clients, 
men who have sex with men, serodiscordant couples, and attendees of sexually transmitted infection clinics.
Findings We identified 57 longitudinal studies exploring the association between HSV-2 and HIV. HIV acquisition 
was almost tripled in the presence of prevalent HSV-2 infection among general populations (adjusted RR 2·7, 95% CI 
2·2–3·4; number of estimates [Ne]=22) and was roughly doubled among higher-risk populations (1·7, 1·4–2·1; 
Ne=25). Incident HSV-2 infection in general populations was associated with the highest risk of acquisition of HIV 
(4·7, 2·2–10·1; Ne=6). Adjustment for confounders at the study level was often incomplete but did not significantly 
affect the results. We found moderate heterogeneity across study estimates, which was explained by risk group, world 
region, and HSV-2 exposure type (prevalent vs incident).
Interpretation We found evidence that HSV-2 infection increases the risk of HIV acquisition. This finding has 
important implications for management of individuals diagnosed with HSV-2 infection, particularly for those who 
are newly infected. Interventions targeting HSV-2, such as new HSV vaccines, have the potential for additional benefit 
against HIV, which could be particularly powerful in regions with a high incidence of co-infection.
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Introduction
HIV and herpes simplex virus type 2 (HSV-2) are 
two global health problems. In 2015, 36·7 million people 
were estimated to be living with HIV/AIDS globally.1 In 
2012, an estimated 417 million people aged 15–49 years 
had HSV-2 infection.2 70% of HIV infections are in 
sub-Saharan Africa, which also has the highest HSV-2 
prevalence.1,2 HSV-2 causes genital herpes, which, when 
symptomatic, is characterised by periodic recurrences 
of painful genital ulcers.3 Although genital herpes 
is asymptomatic or unrecognised in about 80–90% 
of individuals, asymptomatic viral reactivation and 
shedding are common.3 Thus, although individuals 
with HSV-2 are most infectious when they are 
symptomatic, most transmissions are thought to occur 
when the source partner is asymptomatic.4 Genital 
HSV-2 infection can considerably affect relationships 
through feelings of shame and stigma and concerns 
about risk of transmission.5,6
HIV and HSV-2 are both lifelong sexually transmitted 
infections (STIs) that are associated with similar risk 
factors (eg, age, sex, partner change rate, condom use, 
male circumcision).7–10 Additionally, evidence exists of 
direct and reciprocal biological interactions between HIV 
and HSV-2.11,12 Active HSV-2 infection, regardless of 
symptoms, involves high concentrations of activated 
CD4-positive T cells, which are target cells for HIV, in the 
genital area and can lead to breaks in the mucosal layer 
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through which HIV can enter.13 Because genital ulceration 
and viral shedding occur most frequently in the first year 
of HSV-2 infection,14–16 the increase in HIV susceptibility 
might be highest for incident HSV-2 infections. Co-
infection with HIV increases HSV-2 genital shedding and 
transmissibility, while HSV-2 infection correlates with 
increased HIV viraemia and transmissibility.17–20
Development of multipurpose prevention products 
that could protect against multiple STIs (eg, topical 
microbicides and oral pre-exposure prophylaxis) 
would provide exciting opportunities to simultaneously 
reduce  the burden of disease of more than one 
infection.21–23 Quantifying the effect of HSV-2 infection 
on HIV acquisition has important public health 
implications, particularly in high-prevalence settings 
where co-infection is common, because prevention of 
HSV-2 infection (with single-purpose or multipurpose 
prevention tools) might indirectly prevent HIV infection. 
Although trials of use of daily suppressive antiviral 
therapy against HSV-2 have not shown reduced risk of 
HIV acquisition or transmission,24–26 perhaps because 
agents were not used at sufficient doses or for sufficient 
duration, new vaccines against HSV-2 that are currently 
under development27 could hold more promise for HIV 
prevention.
Two systematic reviews and meta-analyses of the 
association between HSV-2 infection and subsequent 
HIV acquisition have been done: one in 200212 and the 
other in 200611 (the one in 2006 was briefly updated in 
an editorial28). These reviews reported a two to three 
times increase in the risk of HIV infection with 
baseline prevalent HSV-2 infection;11,12 estimates of the 
association tended to be lower for high-risk populations 
than for low-risk populations. Here we update and 
substantially augment these reviews to modernise our 
understanding of the interaction between HSV-2 
infection and HIV, in line with the pace of advancing 
prevention efforts against HSV-2 and HIV.
Research in context
Evidence before this study
Herpes simplex virus type 2 (HSV-2) and HIV are both lifelong 
infections sharing common risk factors and widely co-occur 
geographically. Two meta-analytic systematic reviews of 
longitudinal studies have been published to date and have 
shown the adjusted risk of HIV acquisition among individuals 
with prevalent HSV-2 infection to be two to three times the risk 
in those without. This increased risk is thought to be caused by 
the recruitment of activated CD4-positive T cells to the genital 
area, which are target cells for HIV, and breaks in the protective 
epithelial layer during active HSV-2 infection. However, the 
most recent of these reviews is now more than a decade old and 
only included 19 studies, limiting the scope for assessing the 
effect of heterogeneity and study quality. The substantial 
number of new studies published on the subject since then 
allows for more in-depth investigation, including, for the first 
time, quantification of the effect of exposure to incident in 
addition to prevalent HSV-2 infection on pooled estimates of 
the association with HIV acquisition. For this systematic review 
and meta-analysis, we searched PubMed, MEDLINE, and 
Embase between Jan 1, 2003, and May 25, 2017, for studies of 
the association between incident or prevalent HSV-2 infection 
and HIV infection. Studies were included if they were a cohort 
study, controlled trial, or case-control study (including 
case-control studies nested within a cohort or controlled trial); 
were designed to assess the effect of preceding HSV-2 infection 
on HIV acquisition; and used a type-specific antibody assay to 
determine HSV-2 infection (serostatus). 57 longitudinal studies 
met our inclusion criteria, which was 38 more than the last 
systematic search and review (by Freeman and colleagues).
Added value of this study
We report that the pooled adjusted risk of HIV acquisition after 
incident HSV-2 infection is almost five times the risk without 
HSV-2 infection and almost twice the risk associated with 
exposure to prevalent HSV-2 infection. These findings provide a 
strong indication for a biological effect of HSV-2 infection on 
HIV, because the frequency and severity of genital ulceration, 
viral shedding, and associated inflammation in the genital tract 
are highest in new HSV-2 infections and tend to decrease with 
time after infection. The association was higher among general 
populations than among higher-risk populations. Study-level 
adjustment for confounders was often incomplete, but did not 
meaningfully affect the association when comparing crude and 
adjusted pooled estimates. Heterogeneity across study 
estimates was moderate. We extended previous reviews 
through detailed assessment of heterogeneity using 
meta-regression and sub-pooling and through extensive 
assessment of potential biases. We found limited evidence of 
publication bias.
Implications of all the available evidence
Our results provide evidence in support of a direct effect of 
HSV-2 infection on HIV acquisition, which is strengthened by 
our finding of significantly higher HIV risk associated with 
incident HSV-2 infection than with prevalent HSV-2 infection. 
At the population level, new interventions targeting HSV-2, 
such as new vaccines or microbicides, could have an additional 
indirect benefit on HIV as a consequence of the interactions 
between HIV and HSV-2. Such synergies could greatly enhance 
the effect of combination prevention for HIV infection, 
particularly in settings with high HIV prevalence. The 
magnitude of this public health benefit now needs to be 
carefully estimated for different settings by use of 
mathematical models informed by the most recent evidence 
of the associations between HSV and HIV.
Articles
www.thelancet.com/infection   Vol 17   December 2017 1305
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we searched 
PubMed, MEDLINE, and Embase between Jan 1, 2003, 
and May 25, 2017, to identify studies of the relative risk 
(RR) of HIV acquisition after exposure to HSV-2 infection 
either at baseline (ie, prevalent infection) or during 
follow-up (ie, incident infection), published since the 
review by Freeman and colleagues.11 For PubMed, we 
searched for articles and abstracts using the terms 
(“HIV”, “human immunodeficiency virus”, “human 
immunedeficiency virus”, “human immune deficiency 
virus”, OR “human immuno deficiency virus”) AND 
(“HSV”, “herpes simplex”, “herpes virus type 2”, “herpes 
virus 2”, “herpesvirus 2”, “genital herpes” OR “herpes 
genitalis”). Articles in PubMed were also searched with 
the Medical Subject Headings terms (“herpes simplex” 
OR “simplexvirus”) AND (“human immunodeficiency 
virus”, “HIV infection”, “HIV antibodies”, “HIV 
seronegativity”, OR “HIV seroprevalence”). We included 
studies if they were a cohort study, controlled trial, or 
case-control study (including case-control studies nested 
within a cohort or controlled trial); were designed to 
assess the effect of preceding HSV-2 infection, compared 
with HSV-2 negativity, on HIV acquisition (ie, excluding 
case-control studies based on samples from only one 
point in time and studies that only looked at the effect of 
pre-existing HIV infection on HSV-2 acquisition); and 
determined the HSV-2 infection status of study 
participants with an antibody-type-specific assay.
Individuals were defined as HSV-2 negative (unexposed) 
if they remained HSV-2 seronegative throughout follow-
up (preferably) or were HSV-2 seronegative at baseline (for 
those studies in which HSV-2 testing was not done during 
follow-up; repeat testing that was done but not reported 
was noted as a possible source of reporting bias for the 
subsequent assessment of study quality). For full details of 
the search, selection criteria, and data extraction, see the 
appendix.
For studies measuring incident HSV-2 infection, we 
classified RR estimates of HIV acquisition after exposure to 
incident HSV-2 infection into five subcategories for timing 
sequence. These subcategories reflected uncertainty in the 
exact timing of HSV-2 and HIV seroconversion: (1) HSV-2 
seroconversion was observed in a previous time interval 
and thus HSV-2 infection happened before HIV (definitely 
before); (2) HSV-2 seroconversion was observed in the 
same time interval as HIV seroconversion and so HSV-2 
infection might have happened before or after HIV 
infection (indeterminably close); (3) HSV-2 seroconversion 
was observed in a previous or in the same time interval as 
HIV seroconversion (before and indeterminably close); 
(4a) some HSV-2 seroconversion might have occurred after 
HIV infection (maybe after and indeterminably close 
or before); and (4b) some HSV-2 seroconversion was 
observed after HIV infection (after and indeterminably 
close or before; appendix).
Two authors (KJL and JARE) did the systematic review 
and meta-analysis, according to PRISMA29 and MOOSE30 
guidelines. Conflicts about inclusion were resolved 
through discussion between reviewers.
Data analysis
Based on previous evidence suggesting differential 
susceptibility to HIV and HSV-2 by sex,7–9 after exposure 
to incident HSV-2 infection,14–16 and by risk behaviour,10 
we defined a priori that our primary outcomes would be 
pooled RR estimates of the association between incident 
HIV infection and pre-existing prevalent or incident 
HSV-2 infection, for both women and men and by risk 
group (general population vs higher-risk populations), 
also allowing for comparisons with previous pooled 
estimates.11 Higher-risk populations included female sex 
workers and their clients, men who have sex with men, 
serodiscordant couples, and attendees of STI clinics. No 
other stratification was used. To minimise biases due to 
reverse causation, pooled RR estimates for the association 
between HIV infection and exposure to incident HSV-2 
infection were restricted to study estimates when HSV-2 
seroconversion was definitely known to have occurred 
before HIV seroconversion.
To assess study quality, we used the Newcastle-Ottawa 
Scale31 to define nine criteria assessing selection of study 
participants, sample representativeness, exposure or 
outcome ascertainment, and confounding for the extracted 
information about participant and study characteristics. A 
star was awarded for each predetermined criterion that was 
met (appendix). This assessment was done at the estimate 
level, not the study level. The effect of the number of stars 
awarded and other measures of study quality related to 
study characteristics on RR estimates was subsequently 
explored with meta-regression and subgroup analyses.
We investigated the effect of heterogeneity across 
independent RR estimates using the I² statistic.32 Sources 
of heterogeneity were explored with univariate 
meta-regression analysis of independent adjusted RR 
estimates, which estimated the fraction of the between-
study variance in adjusted RR estimates (ie, R²) explained 
by participant characteristics (eg, world region), study 
characteristics (eg, study design), and study quality (eg, 
number of Newcastle-Ottawa Scale stars). Multivariate 
meta-regression analysis was also done with estimates 
for exposure to prevalent HSV-2 infection, but not with 
estimates for exposure to incident HSV-2 infection 
because of the small number of estimates (Ne). 
Additionally, we did separate subgroup analyses of 
adjusted RR estimates for the incident and prevalent 
HSV-2 exposures (appendix).
Publication bias was assessed quantitatively at the 
estimate level, not the study level, in two ways. First, we 
produced funnel plots33 and did Egger’s test for 
publication bias34 for both crude RR and adjusted 
RR estimates and for exposure to prevalent compared 
with exposure to incident HSV-2 infection (appendix). 
See Online for appendix
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Second, we assessed with meta-regression analysis 
whether crude RR estimates calculated from the available 
data were less likely to be significant than those provided 
directly in the paper. Third, we qualitatively assessed 
whether there was evidence of selective reporting of 
significant results.
All meta-analyses, meta-regressions, subgroup 
analyses, and forest plots were done with R version 3.2.2. 
We derived pooled RR estimates with natural log-
transformed study estimates and SEs with random-effect 
models, based on the DerSimonian-Laird inverse-
variance method,35 using the metafor package in R.36 
Pooled estimates were then back-transformed to the 
original scale (further details in the appendix).
Role of the funding source
This study was funded by WHO through the Unified 
Budget, Results and Accountability Framework 
(UBRAF) from the Joint United Nations Programme on 
HIV/AIDS (UNAIDS). SLG from WHO commissioned 
the study, contributed to the direction of the work, and 
commented on the drafts. KJL and JARE had full access 
to all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
We identified 96 relevant publications from 
57 independent studies in the systematic review (figure 1). 
54 studies reported on the RR of HIV acquisition after 
exposure to prevalent HSV-2 infection and 28 studies 
reported on the RR of HIV acquisition after exposure to 
incident HSV-2 infection (table 1; appendix). More 
studies reported on men than on women and on female 
sex workers, men who have sex with men, and other 
higher-risk groups than on general populations (table 1). 
Most studies were done in Africa, in populations where 
baseline HSV-2 prevalence was greater than 30%, and 
were observational cohort studies with follow-up 
exceeding 1 year. Additionally, most studies tested for 
HIV every 6 months or more frequently and defined the 
unexposed group for exposure to prevalent HSV-2 
infection as participants who were HSV-2 (sero)negative 
at baseline. Key potential confounders that were adjusted 
for included age and sexual behaviour, while several 
studies inappropriately adjusted for genital ulcer disease.
39 studies reported 55 adjusted RR estimates for our 
primary outcome: HIV acquisition after exposure to 
prevalent or incident HSV-2 infection (timing of HSV-2 
infection definitely before HIV infection) among general 
and higher-risk populations, by sex (figure 2). No significant 
differences were seen in the associations among general 
populations by sex. The overall pooled adjusted RR for 
general populations was 2·7 (95% CI 2·2–3·4; Ne=22; 
I²=59%) for exposure to prevalent HSV-2 infection and 4·7 
(2·2–10·1; Ne=6; I²=64%) for exposure to incident HSV-2 
infection. The results for higher-risk populations were 
similar to those for general populations, but the magnitude 
of the associations was lower: the overall pooled adjusted 
RR estimate for higher-risk populations was 1·7 (1·4–2·1; 
Ne=25; I²=45%) for exposure to prevalent HSV-2 infection 
and 2·9 (1·7–5·0; Ne=2; I²=0%) for exposure to incident 
HSV-2 infection.
50 studies reported on 64 crude RR estimates for our 
primary outcome (appendix). Pooled crude RR estimates 
overall and by sex were similar to pooled adjusted RR 
estimates, although the pooled crude RR estimates for 
exposure to incident HSV-2 infection were somewhat 
higher than the adjusted RR estimates for general 
populations and were lower than the adjusted RR 
estimates for higher-risk populations. Crude estimates 
were generally more heterogeneous than adjusted 
estimates (figure 2; appendix).
In the univariate meta-regression analysis of 
48 independent adjusted estimates (Ne=40 for prevalent 
HSV-2 infection; Ne=8 for incident HSV-2 infection), 
only risk group (higher-risk population vs general 
6037 publications identified from PubMed, MEDLINE, and Embase
1469 duplicate publications removed
4658 abstracts examined (or title if no abstract was available)
4191 non-relevant publications removed
377 full-text articles retrieved for more detailed examination
311 publications excluded on the basis of selection 
 criteria (including 2 papers not retrieved)
30 additional relevant publications identified
 21 identified through searches of reference
 lists
 9 identified from a previous systematic review
         8 identified from a parallel search*
96 publications from 57 studies investigated HIV incidence in 
 HSV-2 seropositive versus HSV-2 seronegative individuals
55 studies had available estimates for effect of prevalent or 
 incident HSV-2 infection on HIV acquisition
2 studies not included in the analysis
 1 reported the significance of the association
       but no estimates
 1 investigated the association but did not
       report any findings
Figure 1: Study selection
*The search was done in parallel by two reviewers (KJL and JARE). The results for one reviewer are shown; the 
results were very similar between the two reviewers. Each reviewer found eight publications to be relevant that the 
other reviewer did not. HSV-2=herpes simplex virus type 2.
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Prevalent HSV-2 infection* Incident HSV-2 infection†
Number of 
studies (n=54) 
Number of estimates Number of 
studies (n=28)
Number of estimates
Crude RR Adjusted RR Crude RR Adjusted RR
Participant characteristics
Mean or median age‡§
≤25 years 15 18 17 10 9 12
>25 years 39 68 54 20 31 35
Not reported 2 4 1 1 1 0
Sex‡
All women 28 41 34 11 14 24
General population 11 17 15 4 10 13
Female sex workers 8 9 13 2 1 7
Other higher-risk populations¶ 10 15 6 5 3 4
All men 28 37 31 17 23 19
General population 10 14 18 6 11 13
Men who have sex with men 13 16 9 9 11 3
Other higher-risk populations|| 5 7 4 3 1 3
Women and men combined** 8 12 7 5 4 4
WHO region
Africa 35 64 56 16 27 38
Americas 8 11 5 5 7 3
Europe 1 1 0 1 1 0
Eastern Mediterranean 0 0 0 0 0 0
Southeast Asia 5 7 7 4 4 6
Western Pacific 4 4 2 2 2 0
World (not including Africa) 1 3 2 0 0 0
HSV-2 prevalence‡
≤30% 13 14 12 8 8 6
>30% 42 75 59 21 33 41
Not reported 1 1 1 0 0 0
Study characteristics
Study year (mid-point)‡
Pre-2000 16 31 32 11 20 20
2000 onwards 33 54 34 16 19 25
Not reported 6 5 6 2 2 2
Study design
Cohort 27 34 38 15 14 21
Case-control†† 7 8 4 6 7 2
Controlled trial 20 48 30 7 20 24
Study design for analysis of controlled trial data
Prospective 17 33 18 6 10 12
Nested case-control†† 3 15 12 2 10 12
Controlled trial intervention group‡
Intervention 6 8 2 1 2 2
Control 6 8 3 1 2 2
Combined 20 32 25 7 16 20
Overall number of participants for study‡
≤1000 31 49 36 13 23 15
>1000 24 41 36 16 18 32
(Table 1 continues on next page)
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Prevalent HSV-2 infection* Incident HSV-2 infection†
Number of 
studies (n=54)
Number of estimates Number of 
studies (n=28)
Number of estimates
Crude RR Adjusted RR Crude RR Adjusted RR
(Continued from previous page)
Follow-up duration‡
≤1 year 14 22 15 7 11 9
>1 year 37 64 52 18 26 37
Not reported 4 4 5 4 4 1
Length of time between tests for HIV
≤6 months 36 55 41 17 22 27
>6 months 6 17 16 4 12 12
Mixture of short and long intervals 3 4 4 2 3 5
Not reported 9 14 11 5 4 3
HSV-2 assay cutoff (only studies with Focus HerpeSelect as known assay)
1·1/manufacturer’s recommendation/unknown 14 22 15 8 9 13
>1·1 9 11 14 4 4 9
Definition of prevalent HSV-2 infection exposure‡
Baseline 47 79 60 NA NA NA
Baseline and >60 days before HIV seroconversion 1 2 7 NA NA NA
Baseline or >2 years before HIV seroconversion 1 1 1 NA NA NA
Before, or at same visit as, HIV seroconversion 3 5 2 NA NA NA
Same interval as HIV seroconversion 1 1 0 NA NA NA
At visit 6 months before HIV seroconversion 1 1 1 NA NA NA
Anytime 1 1 1 NA NA NA
Definition of incident HSV-2 infection exposure‡
≤60 days before HIV seroconversion NA NA NA 1 0 1
60 days before HIV seroconversion NA NA NA 1 0 5
≤6 months before HIV seroconversion NA NA NA 2 2 1
>6 months before HIV seroconversion NA NA NA 1 1 1
≤2 years before HIV seroconversion NA NA NA 1 1 1
Before, or at same visit as, HIV seroconversion NA NA NA 2 2 1
Visit before HIV seroconversion NA NA NA 1 1 1
Same interval as HIV seroconversion NA NA NA 1 1 0
Anytime NA NA NA 21 33 34
Not reported NA NA NA 1 0 2
Definition of unexposed group‡
HSV-2 negative at baseline 28 40 24 0 0 0
HSV-2 negative throughout follow-up 21 39 40 28 38 44
Not reported 6 11 8 1 3 3
Extraction of crude estimate‡‡‡
Reported 32 45 NA 14 20 NA
Calculated from available data 23 45 NA 11 21 NA
Adjusted for male circumcision status (men or women and men combined)‡§§¶¶
Yes 9 NA 14 5 NA 6
No 15 NA 21 9 NA 17
Unknown 3 NA 3 0 NA 0
Adjusted for condom use‡§§¶¶
Yes 15 NA 25 8 NA 18
No 23 NA 43 12 NA 27
Unknown 4 NA 4 1 NA 2
(Table 1 continues on next page)
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population; R²=31%), world region (Africa vs outside 
Africa; R²=24%), definition of HSV-2 unexposed group 
(HSV-2 negative at baseline vs HSV-2 negative 
throughout follow-up; R²=24%), and HSV-2 exposure 
type (prevalent vs incident; R²=17%) significantly 
explained the variation across study estimates (all 
p<0·05; table 2). The risk of HIV acquisition was about 
twice as large for general populations compared with 
higher-risk populations (RR 0·53, 95% CI 0·38–0·75), 
for Africa compared with outside Africa (0·57, 
0·39–0·82), for incident HSV-2 infection compared with 
prevalent HSV-2 infection (1·96, 1·16–3·31), and when 
the definition for the unexposed group was not reported 
compared with when the definition for the unexposed 
group was HSV-2 negative throughout follow-up (1·84, 
1·08–3·14). Variation across study estimates was not 
explained by confounder adjustment or any of the other 
factors explored, including star rating based on the 
Newcastle-Ottawa Scale. In a multivariate meta-
regression analysis restricted to estimates for prevalent 
Prevalent HSV-2 infection* Incident HSV-2 infection†
Number of 
studies (n=54)
Number of estimates Number of 
studies (n=28)
Number of estimates
Crude RR Adjusted RR Crude RR Adjusted RR
(Continued from previous page)
Adjusted for female hormonal contraceptive use (women or women and men combined)‡§§¶¶
Yes 6 NA 13 4 NA 10
No 16 NA 26 8 NA 16
Unknown 2 NA 2 1 NA 2
Adjusted for any sexual behaviour (excluding condom use)‡§§¶¶
Yes 29 NA 48 16 NA 33
No 8 NA 21 3 NA 12
Unknown 3 NA 3 1 NA 2
Adjusted for genital ulcer disease‡§§¶¶
Yes 9 NA 18 8 NA 16
No 29 NA 51 11 NA 30
Unknown 3 NA 3 1 NA 1
Adjusted for number of sexual partners‡¶¶
Yes 20 NA 33 11 NA 24
No 16 NA 32 8 NA 18
Unknown 5 NA 7 3 NA 5
Adjusted for age‡¶¶
Yes 34 NA 63 14 NA 41
No 8 NA 9 5 NA 5
Unknown 0 NA 0 1 NA 1
Timing of incident HSV-2 infection relative to HIV acquisition‡||||
1 (definitely before) NA NA NA 7 8 14
2 (indeterminably close) NA NA NA 2 2 0
3 (before and indeterminably close) NA NA NA 12 12 11
4a (maybe after and indeterminably close or before) NA NA NA 8 14 17
4b (after and indeterminably close or before) NA NA NA 5 5 5
Type of estimate‡
Hazard ratio 29 31 43 15 13 25
Incidence ratio 17 22 11 8 8 9
Odds ratio 21 37 18 11 20 13
HSV-2=herpes simplex virus type 2. RR=relative risk. NA=not applicable. STI=sexually transmitted infection. *The crude number of estimates for all studies was 90 and the 
adjusted number of estimates for all studies was 72. †The crude number of estimates for all studies was 41 and the adjusted number of estimates for all studies was 47. 
‡Same study included in more than one subcategory. §Values might be estimated from ranges. ¶Women with higher-risk sexual behaviour, women working in food and 
recreational facilities, STI clinic attendees, bar workers, and women in an HIV serodiscordant partnership (grouped with female sex workers in figures). ||Men with higher-risk 
sexual behaviour (likely to be men who have sex with men), STI clinic attendees, male trucking company employees, clients of female sex workers, Thai military conscripts 
(grouped with men who have sex with men in figures). **Estimates by sex could not be obtained. ††All case-control studies were subsequently analysed together. ‡‡Only studies 
providing crude estimates or sufficient information to calculate a crude estimate. §§Includes probable adjustment, and variable not included in multivariate model because of 
non-significance. ¶¶Only studies providing adjusted estimates. ||||Five subcategories for the timing sequence of HSV-2 and HIV seroconversion are defined in Methods.
Table 1: Description of studies and RR estimates of the association between HIV incidence and exposure to HSV-2 infection by participant and study 
characteristics
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0·01 0·1 1 10 100
Adjusted RR (log scale)
He et al (2013)75
Celum et al (2010)26
Higher-risk populations (men and women)
Barnabas et al (2011)74
Li et al (2012)73
Reynolds et al (2003)63*
van Griensven et al (2013)72
Nelson et al (1997)71
Nopkesorn et al (1998)70
Renzi et al (2003)69
Kingsley et al (199)68
Holmberg et al (1988)67
Brown et al (2006)66
Turner et al (2003)65
Rakwar et al (1999)64
Higher-risk populations (men only)
Reynolds et al (2003)63*
Kilmarx et al (1998)62
Nagot et al (2005)61
Mlisana et al (2012)60
Ramjee et al (2005)59
Vandepitte et al (2013)58
Kapiga et al (2013)57
Braunstein (2011 and 2012)55, 56
Masese et al (2015)53
Kapiga et al (2007)54
Masese et al (2015)53
Riedner et al (2006)52
Kaul et al (2004)51
Higher-risk populations (women only)
Guwatudde et al (2009)50
General population (men and women)
Gray et al (2011)44
Sobngwi−Tambekou et al (2009)49
Serwadda et al (2003)43
McFarland et al (1999)48
Todd et al (2006)42
Heffron et al (2011)47
Tobian et al (2009)46
Tobian et al (2009)46
Rositch et al (2014)45
Kebede et al (2004)39
Kamali et al (2003)37*
General population (men only)
Gray et al (2011)44
Mavedzenge et al (2011)41
Mavedzenge et al (2011)41
Mavedzenge et al (2011)41
Mavedzenge et al (2011)41
Serwadda et al (2003)43
Todd et al (2006)42
Mavedzenge et al (2011)41
Mavedzenge et al (2011)41
Brown et al (2007)40
Brown et al (2007)40
Brown et al (2007)40
Brown et al (2007)40
Kebede et al (2004)39
Biraro et al (2013)38
Kamali et al (2003)37*
General population (women only)
1·1 (0·3–3·9)
2·0 (1·1–3·6)
2·2 (1·4–3·5)
4·0 (1·6–10·0)
2·0 (1·4–2·8)
1·5 (1·1–2·1)
3·1 (1·2–7·9)
2·0 (0·6–6·1)
2·8 (0·8–10·1)
0·9 (0·3–2·4)
2·4 (1·1–5·9)
1·5 (1·1–2·1)
1·1 (0·3–4·4)
3·3 (1·2–9·2)
0·5 (0·2–1·1)
0·6 (0·3–1·3)
2·5 (0·7–8·3)
2·1 (0·4–10·5)
0·6 (0·2–1·7)
1·6 (0·6–3·9)
1·8 (0·8–4·1)
1·4 (0·5–3·8)
3·0 (1·6–5·3)
4·3 (1·5–12·4)
2·5 (1·5–4·1)
1·1 (0·4–2·7)
6·3 (1·5–27·1)
8·7 (1·1–67·2)
8·7 (1·1–67·2)
4·9 (2·0–11·8)
3·3 (1·5–7·4)
1·5 (0·9–2·5)
3·5 (2·2–5·8)
3·7 (1·3–10·4)
6·0 (1·7–20·9)
1·1 (0·4–3·1)
2·9 (1·7–4·9)
2·0 (1·0–3·8)
1·3 (0·3–5·3)
7·5 (3·3–16·9)
1·0 (0·5–1·9)
5·4 (0·7–39·5)
3·0 (0·7–13·2)
1·2 (0·6–2·3)
1·6 (1·1–2·5)
2·1 (1·2–3·7)
2·9 (0·9–9·0)
12·6 (4·4–36·3)
2·6 (1·6–4·1)
4·6 (1·6–13·1)
8·6 (4·3–17·1)
2·8 (1·5–5·3)
4·4 (2·7–7·2)
2·3 (0·5–10·6)
3·7 (2·2–6·2)
5·7 (3·0–10·7)
2·5 (1·8–3·4)  68%Pooled estimate (prevalent)
7·2 (4·5–11·5) 0%Pooled estimate (incident)
3·1 (2·2–4·3)  48%Pooled estimate (prevalent)
1·1 (0·4–3·1)   0%Pooled estimate (incident)
  0%Pooled estimate (prevalent)
Pooled estimate (incident)
1·5 (0·9–2·3)  63%Pooled estimate (prevalent)
3·0 (1·6–5·3)   0%Pooled estimate (incident)
1·8 (1·5–2·2)  13%Pooled estimate (prevalent)
  0%Pooled estimate (incident)
1·8 (1·1–3·0)   0%Pooled estimate (prevalent)
Pooled estimate (incident)
2·7 (2·2–3·4)  59%Overall pooled estimate (all prevalent)
4·7 (2·2–10·1)  64%Overall pooled estimate (all incident)
1·7 (1·4–2·1)  45%Overall pooled estimate (all prevalent)
2·9 (1·7–5·0)   0%Overall pooled estimate (all incident)
Adjusted RR (95% CI)     I²Ne
2·8 (0·8–10·1)
HSV-2 exposure type
Incident HSV-2 infection
Prevalent HSV-2 infection
11
5
10
1
1
0
22
6
12
1
11
1
2
0
25
2
Figure 2: Pooled adjusted RR 
estimates of the association 
between HIV incidence and 
exposure to HSV-2 infection
Estimates for effect of both 
prevalent and incident HSV-2 
infection on HIV acquisition 
(timing 1; ie, HSV-2 
seroconversion was observed 
in a previous time interval and 
so definitely occurred before 
HIV seroconversion) are 
shown. Estimates are shown 
for women and men 
combined when they could 
not be obtained separately by 
sex. Multiple estimates for the 
same study corresponding to 
different study countries or 
areas are shown when these 
could not be combined or 
when it was not appropriate to 
do so (ie, countries spanning 
two sub-regions); however, all 
estimates are independent 
(ie, for non-overlapping study 
populations) within each 
HSV-2 exposure subcategory. 
Ne=number of estimates. 
RR=relative risk. HSV-2=herpes 
simplex virus type 2. 
*Data from these studies were 
obtained from reference 11.
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HSV-2 infection, risk group, world region, and definition 
of the HSV-2 unexposed group were all significant 
modifiers of the association with HIV infection (results 
not shown). However, we could not disentangle the 
effect of world region from that of risk group because no 
estimates for general populations were from outside 
Africa.
Figure 3 shows the pooled adjusted RR estimates from 
our subgroup analysis for exposure to prevalent or 
incident HSV-2 infection by key risk factors. Prevalent 
HSV-2 infection was associated with a significantly 
(95% CI did not overlap) higher risk of HIV acquisition 
in general populations (adjusted RR 2·7, 95% CI 2·2–3·4; 
Ne=22; I²=59%) than in higher-risk populations 
(1·7, 1·4–2·1; Ne=25; I²=45%; same as shown in figure 2) 
and in Africa (2·5, 2·1–3·0; Ne=34; I²=52%) than outside 
Africa (1·5, 1·2–2·0; Ne=13; I²=56%), but not for any 
other characteristic explored.
For exposure to incident HSV-2 infection, the risk of 
HIV acquisition was significantly higher in younger 
(≤25 years; adjusted RR 7·6, 95% CI 4·4–13·3; Ne=3; 
I²=0%; figure 3) than in older (>25 years; 2·5, 1·6–3·9; 
Ne=4; I²=3%) individuals; however, no study estimates 
were available for younger individuals in higher-risk 
populations, whereas two of four estimates for older 
individuals were from higher-risk populations. The risk 
of HIV acquisition after exposure to incident HSV-2 
infection was also significantly higher when HIV testing 
was done every 6 months or less (5·0, 3·1–8·1; Ne=7; 
I²=38%) than when tests were done at a mixture of short 
and long intervals (1·1, 0·4–3·1; Ne=1; I²=0%), although 
this analysis was based on only one study. No other 
significant differences were observed, although the 
magnitude of the association tended to be larger for 
women than for men. Notably, most study estimates 
came from women in general populations in Africa. Our 
subgroup analysis showed that pooled adjusted RR 
estimates were increased, although not significantly, 
when exposure to incident HSV-2 infection was known 
to have or might have occurred after HIV (timing 4a and 
4b vs timing 1; figure 3).
The study characteristics relevant to the evaluation of 
study quality, and the results of the Newcastle-Ottawa 
Scale assessment, are summarised in the appendix. Of 
the 55 adjusted estimates included in our principal 
meta-analysis, a seven-star or eight-star rating was the 
most common (Ne=31). The most common reasons for 
loss of a star were defining the HSV-2 unexposed group 
by use of baseline status and no matching or adjustment 
for number of sexual partners. However, a star could 
also be lost if the required information for assessment 
was not reported in the paper, which is not necessarily 
the same as poor study quality. Conversely, a star could 
have been awarded for adequate participant retention 
(low loss to follow-up), which was assessed on the basis 
of the information in the publication but which might 
not have mentioned all dropouts.
Number of 
estimates
Adjusted RR 
(95% CI)
Variance 
explained 
R² (%)
p value
Participant characteristics 
Mean or median age
≤25 years 14 1·00 0% 0·40
>25 years 33 1·34 (0·88–2·04) ·· ··
Not reported 1 1·26 (0·32–4·88) ·· ··
Sex
Women 23 1·00 0% 0·97
Men 22 1·02 (0·68–1·53) ·· ··
Combined* 3 0·90 (0·36–2·25) ·· ··
Risk group
General population 22 1·00 31% 0·0004
Higher-risk population 26 0·53 (0·38–0·75) ·· ··
World region (derived from WHO region)
African region 34 1·00 24% 0·003
Outside Africa 14 0·57 (0·39–0·82) ·· ··
HSV-2 prevalence
≤30% 10 1·00 6% 0·08
>30% 37 0·97 (0·63–1·51) ·· ··
Not reported 1 0·24 (0·07–0·85) ·· ··
Study characteristics
Study year (mid-point)
Pre-2000 18 1·00 0% 0·85
2000 onwards 24 1·13 (0·74–1·71) ·· ··
Not reported 6 1·05 (0·51–2·14) ·· ··
Study design
Cohort 25 1·00 0% 0·69
Controlled trial 15 1·20 (0·77–1·86) ·· ··
Case-control (including nested case-control) 8 0·98 (0·56–1·71) ·· ··
Controlled trial intervention group
Control 0 ·· ·· ··
Intervention 0 ·· ·· ··
Combined 19 NA ·· ··
Follow-up duration
≤1 year 12 1·00 0% 0·97
>1 year 32 0·95 (0·59–1·52) ·· ··
Not reported 4 0·94 (0·39–2·25) ·· ··
Length of time between tests for HIV
≤6 months 31 1·00 0% 0·98
>6 months 6 0·99 (0·55–1·78) ·· ··
Mixture of short and long intervals 3 0·86 (0·37–2·04) ·· ··
Not reported 8 1·07 (0·62–1·84) ·· ··
HSV-2 assay cutoff (only those studies with Focus HerpeSelect as known assay)
1·1/manufacturer’s recommendation/
unknown
12 1·00 19% 0·20
>1·1 7 1·57 (0·79–3·10) ·· ··
(Table 2 continues on next page)
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There was little indication of publication bias from the 
funnel plots (appendix): most study estimates were 
evenly distributed around the overall pooled crude and 
adjusted RR estimates. However, the fewer RR estimates 
available for exposure to incident HSV-2 infection than 
for exposure to prevalent HSV-2 infection made the 
assessment for incident HSV-2 infection more difficult. 
In a meta-regression analysis, crude RR estimates 
calculated from the available data were lower than those 
reported in the studies (0·79, 95% CI 0·57–1·09; 
R²=2·5%; p=0·15), although the difference was not 
significant. Our qualitative assessment found some 
evidence of selective reporting of estimates based on 
significance (eg, studies reporting crude but not 
adjusted estimates or only mentioning the significance 
of an association without presenting any estimates; 
appendix).
Discussion
This systematic review and meta-analysis provided new 
insight into the effect of HSV-2 infection on risk of HIV 
acquisition by analysis of 57 longitudinal studies of 
different study designs. We found good evidence that 
HIV incidence in general populations is roughly tripled 
by exposure to prevalent HSV-2 infection (adjusted 
RR 2·7, 95% CI 2·2–3·4), with an even larger increase in 
HIV risk after exposure to incident HSV-2 infection 
(4·7, 2·2–10·1). The greater cofactor effect for incident 
HSV-2 infection than for prevalent HSV-2 infection might 
be because newly acquired HSV-2 infection is associated 
with an increased frequency and severity of genital 
ulceration, viral shedding, and inflammation in the 
genital tract, symptoms and manifestations that decrease 
with time after infection.14–16 These biological mechanisms 
and gradient in risk strengthen the argument for a 
genuine biological effect of HSV-2 infection on HIV 
acquisition risk.
In addition to differences by prevalent versus incident 
HSV-2 infection, heterogeneity in the magnitude of the 
association across adjusted RR estimates was also 
explained by population risk group. The associations 
remained significant but were somewhat lower 
among higher-risk populations than among general 
populations, perhaps because these populations have an 
increased risk of HIV independent of HSV-2 or because 
higher-risk individuals infected with HSV-2 might be 
more likely to use condoms or abstain from sex when 
symptomatic.
The results of our systematic review and meta-analysis 
were generally in line with, and strengthen results from, 
previous meta-analyses.11,12 The 38 studies published 
since the last systematic search and review,11 and the 
large body of study information extracted, allowed us to 
comprehensively review existing evidence on the 
association between HSV-2 and HIV infections and 
assess the effects of a wide range of factors related to 
participant and study characteristics, including study 
quality, which have not been previously explored. We 
also produced the first pooled estimates of the association 
between exposure to incident HSV-2 infection and 
subsequent HIV acquisition.
Number of 
estimates
Adjusted RR 
(95% CI)
Variance 
explained 
R² (%)
p value
(Continued from previous page)
HSV-2 exposure type
Prevalent 40 1·00 17% 0·01
Incident 8 1·96 (1·16–3·31) ·· ··
Definition of unexposed group
HSV-2 negative throughout follow-up 21 1·00 24% 0·005
HSV-2 negative at baseline 19 0·76 (0·52–1·11) ·· ··
Not reported 8 1·84 (1·08–3·14) ·· ··
Adjusted for male circumcision status (men or women and men combined)
No 15 1·00 0% 0·48
Yes 7 1·33 (0·84–2·10) ·· ··
Not reported 3 1·08 (0·57–2·05) ·· ··
Adjusted for condom use
No 27 1·00 0% 0·88
Yes 17 1·10 (0·72–1·68) ·· ··
Not reported 4 1·13 (0·52–2·48) ·· ··
Adjusted for female hormonal contraceptive use (women or women and men combined)
No 17 1·00 0% 0·70
Yes 7 1·25 (0·58–2·69) ·· ··
Not reported 2 1·82 (0·34–9·81) ·· ··
Adjusted for any sexual behaviour (excluding condom use)
No 9 1·00 0% 0·48
Yes 36 1·39 (0·81–2·37) ·· ··
Not reported 3 1·46 (0·58–3·69) ·· ··
Adjusted for genital ulcer disease
No 36 1·00 10% 0·14
Yes 9 1·54 (0·97–2·45) ·· ··
Not reported 3 1·61 (0·60–4.34) ·· ··
Adjusted for number of sexual partners
No 19 1·00 0% 0·46
Yes 23 0·85 (0·55–1·31) ·· ··
Not reported 6 0·68 (0·36–1·26) ·· ··
Adjusted for age
No 6 1·00 0% 0·99
Yes 42 1·00 (0·54–1·85) ·· ··
Estimate type
Hazard ratio or incidence ratio 39 1·00 0% 0·25
Odds ratio 9 0·74 (0·45–1·23) ·· ··
Study quality (as defined by number of stars awarded with Newcastle-Ottawa scale)
Increase of 1 star (continuous variable) 48 1·00 (0·85–1·17) 0% 0·96
Only independent adjusted RR estimates were included. RR=relative risk. HSV-2=herpes simplex virus type 2. 
NA=not applicable. *Estimates by sex could not be obtained. 
Table 2: Results of univariate meta-regression analysis of adjusted RR estimates
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HSV-2 and HIV are lifelong infections that affect 
genital sites and have similar risk factors, such as 
sexual behaviour, which increases the risk of spurious 
association in observational studies because of 
confounding. We minimised the risk of confounding at 
the study level by focusing our analysis on adjusted 
estimates. However, the risk of residual confounding 
could not be totally eliminated because many potential 
confounding factors were often not controlled for, even 
in adjusted estimates. The presence of HSV-2 infection 
(particularly incident HSV-2 infection) might be a marker 
of having had sex with a partner infected with HIV 
0·1 100 100
Adjusted RR (log scale)
4·1 (2·3–7·2)  58%1 (definitely before) 8
····2 (indeterminably close) 0
2·8 (1·7–4·6)  56%3 (before and indeterminably close) 8
5·7 (4·2–7·7)   04a (maybe after and indeterminably close or before)
 
8
5·5 (3·9–7·6) 6%4b (after and indeterminably close or before) 4
2·8 (0·8–10·1)   0%Outside Africa 1
4·3 (2·3–8·0)  63%Africa 7
1·5 (1·2–2·0)  56%Outside Africa 13
2·5 (2·1–3·0)  52%Africa 34
5·4 (3·2–9·2)  43%Women 6
····Women and men 0
1·6 (0·6–4·1)  25%Men 2
1·9 (1·5–2·6)  69%Women 23
2·0 (1·0–4·2)  28%Women and men 3
2·4 (1·9–2·9)  50%Men 21
3·0 (1·6–5·3)   0%FSWs 1
2·8 (0·8–2·7)   0%MSM 1
1·5 (0·8-2·7)  65%FSWs 7
1·7 (1·4–2·1)  26%MSM 7
4·7 (2·2–10·1)  64%General population 6
2·9 (1·7–5·0)   0%Higher-risk population 2
2·7 (2·2–3·4)  59%General population 22
1·7 (1·4–2·1)  45%Higher-risk population 25
7·6 (4·4–13·3)   0%≤25 years 3
2·5 (1·6–3·9)   3%>25 years 4
····Not reported 0
1·9 (1·3–2·8)  74%≤25 years 16
2·3 (2·0–2·8)  50%>25 years 34
2·4 (1·1–5·9)   0%Not reported 1
····HSV-2 negative at baseline 0
3·4 (1·7–6·7)  67%HSV-2 negative throughout follow−up 5
6·9 (2·8–17·2)  20%Not reported 3
1·8 (1·4–2·2)  33%HSV-2 negative at baseline 20
2·3 (1·8–3·0)  64%HSV-2 negative throughout follow−up 20
2·7 (1·7–4·1)  71%Not reported 8
5·0 (3·1–8·1)  38%≤6 months 7
····>6 months 0
1·1 (0·4–3·1)   0%Mixture of short and long intervals 1
····Not reported 0
2·0 (1·7–2·4)  59%≤6 months 30
2·3 (1·6–3·4)  39%>6 months 6
2·9 (1·9–4·3)   0%Mixture of short and long intervals 3
2·4 (1·3–4·4)  75%Not reported 8
Timing of incident HSV-2 infection relative to HIV acquisition
World region
Incident HSV-2 infection
Prevalent HSV-2 infection
Sex
Incident HSV-2 infection
Prevalent HSV-2 infection
FSWs or MSM
Incident HSV-2 infection
Prevalent HSV-2 infection
Population risk group
Incident HSV-2 infection
Prevalent HSV-2 infection
Mean or median age
Incident HSV-2 infection
Prevalent HSV-2 infection
Definition of unexposed group
Incident HSV-2 infection
Prevalent HSV-2 infection
Length of time between testing for HIV
Incident HSV-2 infection
Prevalent HSV-2 infection
Adjusted RR (95% CI) I²Ne
HSV-2 exposure type
Incident HSV-2 infection
Prevalent HSV-2 infection
Figure 3: Sub-pooled adjusted RR estimates of the association between HIV incidence and exposure to HSV-2 infection
Estimates for effect of both prevalent and incident HSV-2 infection on HIV acquisition (timing 1; ie, HSV-2 seroconversion was observed in a previous time interval 
and so definitely occurred before HIV seroconversion) are shown. Estimates were added for sub-pooling if they were available by subcategories, although only 
independent study estimates were included within a subcategory. RR=relative risk. HSV-2=herpes simplex virus type 2. Ne=number of estimates. FSWs=female sex 
workers. MSM=men who have sex with men.
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because of the higher prevalence of HSV-2 among HIV-
infected than among non-HIV-infected individuals.76–78 
Except for serodiscordant-couple studies, in which 
partner HIV status was known, few studies controlled for 
partner characteristics. Additionally, some studies 
inappropriately adjusted for genital ulcer disease, which 
might have biased pooled estimates toward the null value 
because HSV-2 commonly causes genital ulcers and 
these act as a point of entry for HIV.13 Nevertheless, we 
did not find any notable difference between crude and 
adjusted pooled estimates, and, in the meta-regression 
analysis, we found that adjustment for key confounders 
was not associated with the effect size. Confounding 
could also have arisen from combining estimates from 
heterogeneous studies, which is an important reason for 
doing detailed meta-regression and subgroup analyses. 
Fewer estimates for incident HSV-2 than for prevalent 
HSV-2 increased the risk of confounding when 
combining heterogeneous studies, but also precluded a 
multivariate meta-regression analysis for incident HSV-2 
infection. No estimates were available for general 
populations outside Africa for either prevalent or incident 
HSV-2 infection, meaning that our results might not be 
generalisable to general populations outside this setting. 
Furthermore, our finding of a higher risk of HIV with 
HSV-2 among general populations than among higher-
risk populations could have been confounded by world 
region (or vice versa).
Another potential threat to validity was misclassification 
bias of the exposure to HSV-2 infection. Misclassification 
bias can occur if HSV-2 exposure is defined solely 
according to HSV-2 antibody status at baseline and some 
unexposed individuals seroconvert to HSV-2 during the 
study. Although exposure status was defined solely on 
baseline HSV-2 infection status in half of the studies 
estimating the association between prevalent HSV-2 
infection and HIV acquisition, we found only weak 
indication that the association between HSV-2 and HIV 
was lower in those studies. However, in our meta-
regression analyses, estimates were significantly 
increased for unknown definition of the unexposed 
comparison group, which might be a proxy for poor 
study quality more generally.
To minimise the risk of reverse causation, we only 
included longitudinal studies and categorised estimates 
for effect of incident HSV-2 infection on HIV acquisition 
according to the timing of HSV-2 infection compared 
with HIV seroconversion. For our principal meta-
analysis and meta-regression, we restricted inclusion of 
estimates for incident HSV-2 infection to when incident 
HSV-2 infection was known with greatest certainty to 
have occurred before HIV seroconversion (ie, timing 1), 
excluding any estimates for which HSV-2 infection was 
known to or might have occurred after HIV infection. By 
erring on the side of caution, we might have inadvertently 
excluded estimates for when HSV-2 infection occurred 
before HIV in studies where testing was not done 
sufficiently frequently to disentangle the sequence of 
infection. However, those estimates that included known 
or possible HIV infection before HSV-2 acquisition were 
not significantly different to our estimate for timing 1.
Our qualitative assessment of selective reporting of 
crude and adjusted estimates based on significance found 
some evidence of publication bias. However, publication 
bias was not significant from either funnel plots or our 
meta-regression comparing reported crude estimates 
with crude estimates derived from available data. We did 
not find any evidence in our meta-regression that study 
quality influenced the association between HSV-2 and 
HIV, except where the definition of HSV-2 negative was 
not reported, which was associated with a significantly 
increased risk of HIV acquisition due to HSV-2.
Understanding the effect of HSV-2 infection on HIV risk 
is essential for several reasons. From a clinical perspective, 
knowledge of this association informs the advice and 
information given to individuals diagnosed with genital 
herpes, who might be at increased risk of acquiring HIV. 
Much, if not most, of HSV-associated HIV transmission is 
thought to occur outside symptomatic episodes, including 
among individuals who harbour HSV-2 infection but have 
never had symptoms of genital herpes. Thus, from a 
population perspective, understanding the interaction 
between HSV-2 and HIV is also important for informing 
public health interventions for the control of both 
infections, because an intervention targeting HSV-2 might 
have additional, indirect benefits on HIV.
Current prevention and treatment options for HSV-2 
infection are imperfect and limited by the often 
asymptomatic presentation of HSV-2 infection.3 
However, development of new interventions is underway. 
Multipurpose prevention technologies (eg, microbicides) 
that target both HIV and HSV-2 infection hold promise, 
but developments have been hampered by low 
compliance and acceptability among women.22 The best 
option is likely to be an effective vaccine against HSV-2 
infection. Efforts to develop an HSV-2 vaccine are 
underway.27 HSV-2 infection is a common infection 
globally, but has a particularly high incidence in specific 
settings where HIV is endemic, such as sub-Saharan 
Africa, and among higher-risk groups, who are important 
in concentrated HIV epidemics. Therefore, addressing 
the interactions between HSV-2 and HIV could produce 
substantial health and economic gains. This meta-
analysis is an important step towards clearer 
quantification of the potential magnitude of that benefit.
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